Aster DM Healthcare (ASTERDM) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue grew 20% year-over-year to INR 1,002 crore, with operating EBITDA up 39% to INR 177 crore and PAT (post-NCI) up 80% to INR 74 crore.

• Focus shifted exclusively to India after GCC business segregation, positioning for growth in a market with low hospital bed density and significant healthcare infrastructure needs.

• Recognized as Best Healthcare Brand of the Year 2024, achieved NABH Digital Platinum Accreditation for Aster CMI, and received multiple national awards for hospital excellence and CSR initiatives.

• Board approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2024, with a limited review by auditors and no material misstatements found.

• Four new directors were appointed, including two independent and two non-independent directors, effective 31 July 2024.

Financial highlights

• Q1 FY25 India revenue rose 20% year-over-year to INR 1,002 crore; operating EBITDA up 39% to INR 177 crore, margin at 17.7%.

• Net profit post NCI grew 80% to INR 74 crore, driven by operational excellence and investment income.

• Standalone net profit for the quarter was INR 6,008.24 crores, and consolidated net profit was INR 5,152.20 crores, both primarily due to a one-time gain from the sale of the GCC business.

• Core hospital and clinic segment revenue up 21% to INR 968 crore; operating EBITDA margin at 20.8%.

• ARPOB increased 12% year-over-year to INR 44,200; mature hospitals delivered 23% EBITDA margin and 30% ROCE.

Outlook and guidance

• Blended EBITDA margin expected to rise from current 17.7% to 20-21% in the next few years; core hospital segment margin targeted at 23-24%.

• ARPOB growth projected at 7-8% CAGR over the next 3-4 years, with 3-4% from price increases and the rest from case mix.

• Expansion to 6,500 beds by FY27 on track, with 60% of new beds from brownfield projects.

• Strategic focus on brownfield/greenfield investments, specialty mix improvement, asset-light models, and digital health expansion.

• The company completed the separation of its GCC business on 3 April 2024, with the GCC segment now classified as discontinued operations.